BioXyTran, Inc. is a pharmaceutical company, which engages in the development, manufacturing and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its products include BXT-25, an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. The company was founded on October 5, 2017 and is headquartered in Newton, MA.